CA Patent

CA2267743C — Low dose estrogen interrupted hormone replacement therapy

Assigned to Jencap Research Ltd · Expires 2011-07-26 · 15y expired

What this patent protects

A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses. being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phrase comprising three daily d…

USPTO Abstract

A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses. being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phrase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17.beta.-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17.beta.-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 µg per day of norgestimate.

Drugs covered by this patent

Patent Metadata

Patent number
CA2267743C
Jurisdiction
CA
Classification
—
Expires
2011-07-26
Drug substance claim
No
Drug product claim
No
Assignee
Jencap Research Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.